Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

FDA Apporoves ‘Alhemo’ to Help Hemophilia Patients Manage Bleeding

Daniel Kim Views  

Novo Nordisk\'s hemophilia treatment has received approval from the U.S. FDA. / Medical Today
Novo Nordisk’s hemophilia treatment has received approval from the U.S. FDA. / Medical Today

Novo Nordisk’s hemophilia treatment has received approval from the U.S. Food and Drug Administration (FDA). The FDA has approved Novo Nordisk’s Alhemo to reduce bleeding in hemophilia patients.

Hemophilia is a condition that impairs the body’s ability to form blood clots, leading to prolonged bleeding episodes. In the United States, approximately 33,000 individuals are affected by this disorder.

Current hemophilia treatments primarily involve replacement therapy, which administers clotting factors to normalize the blood clotting process. However, 30% of patients with hemophilia A and 5% to 15% of those with hemophilia B develop antibodies against these clotting factors, reducing the effectiveness of traditional replacement therapy.

Alhemo is approved for use in adolescents and adults aged 12 and older who have developed such antibodies. Administered via subcutaneous injection, Alhemo aims to enhance the effectiveness of replacement therapy and reduce bleeding.

Meanwhile, current hemophilia treatments include Pfizer’s injection HYMPAVZI, approved in October, and several gene therapies.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Why Your Eyelid Keeps Twitching—and When to Worry
  • Silent Spreaders: How Measles Can Infect Before Symptoms Appear
  • Eat More Eggplant—It’s Good for Your Blood and Your Heart
  • Want to Burn More Fat? Try a 30-Second Cold Shower, Experts Say
  • Bats, Fruit, and a Deadly Virus—Why Korea’s Health Officials Are on High Alert
  • Why You Crave Junk Food When You’re Sad—And What to Eat Instead

You May Also Like

  • 1
    Sizzling Summer: Southeast US Breaks Heat Records as Temperatures Soar

    LATEST 

  • 2
    GSK Korea’s New Boss: What Gunnar Riediger Brings to the Table!

    LATEST 

  • 3
    Is Tesla Behind LG Energy's Massive Battery Supply Contract?

    LATEST 

  • 4
    New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!

    LATEST 

  • 5
    Korean President Aims to Cut Red Tape and Boost Business with New Task Force

    LATEST 

Popular Now

  • 1
    Beat the Heat: Agoda's Top 5 Cool-Cation Spots for Summer Travelers!

    LATEST 

  • 2
    Brace Yourself: Prices on Everyday Goods Set to Rise as Tariffs Take Their Toll

    LATEST 

  • 3
    Former Intel Chief Drops Bombshell: Yoon's Fury Over Marine's Death Revealed!

    LATEST 

  • 4
    Taiwan's President Delays Trip to the Americas Amid Typhoon Chaos

    LATEST 

  • 5
    Buddhist Monk’s Prediction Comes True: Annuity Lottery Winner Shares His Story!

    LATEST 

Must-Reads

  • 1
    Sizzling Summer: Southeast US Breaks Heat Records as Temperatures Soar

    LATEST 

  • 2
    GSK Korea’s New Boss: What Gunnar Riediger Brings to the Table!

    LATEST 

  • 3
    Is Tesla Behind LG Energy's Massive Battery Supply Contract?

    LATEST 

  • 4
    New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!

    LATEST 

  • 5
    Korean President Aims to Cut Red Tape and Boost Business with New Task Force

    LATEST 

Popular Now

  • 1
    Beat the Heat: Agoda's Top 5 Cool-Cation Spots for Summer Travelers!

    LATEST 

  • 2
    Brace Yourself: Prices on Everyday Goods Set to Rise as Tariffs Take Their Toll

    LATEST 

  • 3
    Former Intel Chief Drops Bombshell: Yoon's Fury Over Marine's Death Revealed!

    LATEST 

  • 4
    Taiwan's President Delays Trip to the Americas Amid Typhoon Chaos

    LATEST 

  • 5
    Buddhist Monk’s Prediction Comes True: Annuity Lottery Winner Shares His Story!

    LATEST 

Share it on...